NCT03051477: Dose Escalating Trial of Mistletoe Extract in Patients With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 100 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with a known history or evidence of brain metastases; Patient who has had any prior treatment with Mistletoe (injection or infusion)

Comments are closed.

Up ↑